Literature DB >> 31504790

Dietary vitamin D interacts with high phosphate-induced cardiac remodeling in rats with normal renal function.

Ming Chang Hu1,2, Roberto Scanni1,3,4, Jianfeng Ye1, Jianning Zhang2, Mingjun Shi1, Jenny Maique1, Brianna Flores1, Orson W Moe1,2,5, Reto Krapf3,4.   

Abstract

BACKGROUND: Vitamin D (VD) and phosphate (Pi) load are considered as contributors to cardiovascular disease in chronic kidney disease and the general population, but interactive effects of VD and Pi intake on the heart are not clearly illustrated.
METHODS: We fed normal male rats with three levels of dietary VD (100, 1100 or 5000 IU/kg chow) and Pi (0.2, 0.6 or 1.6%) (3X3 design) for 8 weeks and examined renal and cardiac function and histology.
RESULTS: High dietary Pi decreased plasma and renal Klotho and plasma 25-hydroxyvitamin D, and increased plasma Pi, fibroblast growth factor 23 and parathyroid hormone without affecting renal function, while low Pi increased plasma and renal Klotho. Both low and high VD diets enhanced high Pi-reduced Klotho expression. Low dietary VD reduced-plasma Klotho was rescued by a low Pi diet. High dietary Pi reduced-cardiac ejection fraction was not modified by a low or high VD diet, but the dietary VD effects on cardiac pathologic changes were more complex. High dietary Pi-induced cardiac hypertrophy was attenuated by a low VD and exacerbated by a high VD diet. In contrast, high dietary Pi -induced cardiac fibrosis was magnified by a low VD and attenuated by a high VD diet.
CONCLUSIONS: High Pi diet induces hypertrophy and fibrosis in left ventricles, a low VD diet accelerates high Pi-induced fibrosis, and a high VD diet exacerbated high Pi -induced hypertrophy. Therefore, cardiac phosphotoxicity is exacerbated by either high or low dietary VD in rats with normal kidney function.
© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  Klotho; cardiac fibrosis; cardiac hypertrophy; phosphate; vitamin D

Mesh:

Substances:

Year:  2020        PMID: 31504790      PMCID: PMC7057543          DOI: 10.1093/ndt/gfz156

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  52 in total

Review 1.  Fibroblast growth factor 23/klotho axis in chronic kidney disease.

Authors:  Kosaku Nitta; Nobuo Nagano; Ken Tsuchiya
Journal:  Nephron Clin Pract       Date:  2014-11-08

2.  Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.

Authors:  Alexander Grabner; Ansel P Amaral; Karla Schramm; Saurav Singh; Alexis Sloan; Christopher Yanucil; Jihe Li; Lina A Shehadeh; Joshua M Hare; Valentin David; Aline Martin; Alessia Fornoni; Giovana Seno Di Marco; Dominik Kentrup; Stefan Reuter; Anna B Mayer; Hermann Pavenstädt; Jörg Stypmann; Christian Kuhn; Susanne Hille; Norbert Frey; Maren Leifheit-Nestler; Beatrice Richter; Dieter Haffner; Reimar Abraham; Johannes Bange; Bianca Sperl; Axel Ullrich; Marcus Brand; Myles Wolf; Christian Faul
Journal:  Cell Metab       Date:  2015-10-01       Impact factor: 27.287

3.  Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy.

Authors:  Ming Chang Hu; Mingjun Shi; Nancy Gillings; Brianna Flores; Masaya Takahashi; Makoto Kuro-O; Orson W Moe
Journal:  Kidney Int       Date:  2017-01-25       Impact factor: 10.612

Review 4.  Vitamin D and inflammation.

Authors:  Uwe Querfeld
Journal:  Pediatr Nephrol       Date:  2012-12-13       Impact factor: 3.714

5.  Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy.

Authors:  A Piovesan; N Molineri; F Casasso; I Emmolo; G Ugliengo; F Cesario; G Borretta
Journal:  Clin Endocrinol (Oxf)       Date:  1999-03       Impact factor: 3.478

6.  Wheat germ agglutinin staining as a suitable method for detection and quantification of fibrosis in cardiac tissue after myocardial infarction.

Authors:  B Emde; A Heinen; A Gödecke; K Bottermann
Journal:  Eur J Histochem       Date:  2014-12-17       Impact factor: 3.188

Review 7.  Phosphate levels and cardiovascular disease in the general population.

Authors:  Robert N Foley
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-07       Impact factor: 8.237

8.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.

Authors:  Elisabeth M Zeisberg; Oleg Tarnavski; Michael Zeisberg; Adam L Dorfman; Julie R McMullen; Erika Gustafsson; Anil Chandraker; Xueli Yuan; William T Pu; Anita B Roberts; Eric G Neilson; Mohamed H Sayegh; Seigo Izumo; Raghu Kalluri
Journal:  Nat Med       Date:  2007-07-29       Impact factor: 53.440

9.  Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3-5: The Modification of Diet in Renal Disease Study.

Authors:  Umut Selamet; Hocine Tighiouart; Mark J Sarnak; Gerald Beck; Andrew S Levey; Geoffrey Block; Joachim H Ix
Journal:  Kidney Int       Date:  2016-01-04       Impact factor: 10.612

10.  Autophagy, apoptosis, vitamin D, and vitamin D receptor in hepatocellular carcinoma associated with hepatitis C virus.

Authors:  Mohamed Ahmed Abdel-Mohsen; Ahlam Abd-Allah El-Braky; Abeer Abd El-Rahim Ghazal; Mohammed Mohammed Shamseya
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

View more
  3 in total

Review 1.  Phosphate Is a Cardiovascular Toxin.

Authors:  Maren Leifheit-Nestler; Isabel Vogt; Dieter Haffner; Beatrice Richter
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 2.  FGF23 and Phosphate-Cardiovascular Toxins in CKD.

Authors:  Isabel Vogt; Dieter Haffner; Maren Leifheit-Nestler
Journal:  Toxins (Basel)       Date:  2019-11-06       Impact factor: 4.546

3.  High Phosphate Induces and Klotho Attenuates Kidney Epithelial Senescence and Fibrosis.

Authors:  Jenny Maique; Brianna Flores; Mingjun Shi; Sierra Shepard; Zhiyong Zhou; Shirely Yan; Orson W Moe; Ming Chang Hu
Journal:  Front Pharmacol       Date:  2020-08-20       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.